Ernexa Therapeutics Inc. (ERNA) Research

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

Market snapshot

Symbol
ERNA
Price
$6.20
Day change
+5.26%
Market cap
$1.9M
P/E ratio
-0.43x
52-week range
3.18-71.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Ernexa Stock Is Jumping Today: What's Going On?

    Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are skyrocketing Tuesday. The market is seemingly reacting to the company's latest investor segment featuring Chief Scientific Officer Dr. Robert Pierce, along with fresh attention on the potential of ERNA‑101 in ovarian cancer.

Peer companies

  • Adaptimmune Therapeutics plc (ADAP)
  • Aethlon Medical, Inc. (AEMD)
  • AEON Biopharma, Inc. (AEON)
  • Dogwood Therapeutics, Inc. (DWTX)
  • Lunai Bioworks Inc. (LNAI)
  • Moleculin Biotech, Inc. (MBRX)
  • MapLight Therapeutics, Inc. (MPLT)
  • OSR Holdings, Inc. (OSRH)

Recent insider activity

  • Cherington Charles — P-Purchase (4000000 shares) on 2026-02-10
  • Cherington Charles — P-Purchase (4000000 shares) on 2026-02-10
  • Gurrola Sandra M — M-Exempt (30 shares) on 2025-06-21
  • Gurrola Sandra M — M-Exempt (30 shares) on 2025-06-21
  • Cherington Charles — P-Purchase (21241163 shares) on 2025-06-09

Open Ernexa Therapeutics Inc. (ERNA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.